TR-Pharm has begun working on the technology transfer. This collaboration will be an important part of TR-Pharm’s ongoing biologic product development and manufacturing business in the region. The partnership also allows Dr. Reddy’s to expand the global footprint of its biosimilar business.
Mehmet Göker, general manager of TR-Pharm, said, “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country. We are pleased to have already started laying out the groundwork for manufacturing with Dr. Reddy’s for high quality biosimilar products.”
M V Ramana, executive vice president and head Branded Markets at Dr. Reddy’s, said, “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr. Reddy’s remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”